Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | CNR2 | P34972 | 12/20 | 0.79 |
| ▸ | CNR1 | P21554 | 9/20 | 0.79 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545257 | 1.00 | DRD3 (1.00) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL13883182 | 1.00 | DRD3 (1.00) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL23601989 | 1.00 | DRD3 (1.00) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL25953754 | 0.96 | DRD3 (0.93) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL12590215 | 0.88 | CNR2 (1.00) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL31545240 | 0.88 | CNR2 (1.00) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL23601940 | 0.88 | CNR2 (1.00) | DRD3CNR2CNR1GLRA1NR1I2 | |
| SCHEMBL31545693 | 0.88 | DRD3 (0.78) | DRD3CNR2CNR1GLRA1 | |
| SCHEMBL31546040 | 0.88 | DRD3 (0.78) | DRD3CNR2CNR1GLRA1 | |
| SCHEMBL17388329 | 0.85 | DRD3 (0.74) | DRD3CNR2CNR1GLRA1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | claimed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | claimed |
| US-20140194514-A1 | TOPICAL FORMULATIONS | TARAXOS INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130209585-A1 | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy | KIM STANLEY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110178177-A1 | TOPICAL FORMULATIONS FOR TREATMENT OF NEUROPATHY | TARAXOS INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110129508-A1 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF PAIN USING OMEGA-CONOTOXINS | RELEVARE AUST. PTY LTD (AU) | 2011-06-02 | — | — | US | disclosed |
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | disclosed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | disclosed |
| EP-1441635-A2 | STERILE, BREATHABLE PATCH FOR TREATING WOUND PAIN | EpiCept Corporation (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1438020-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EpiCept Corporation (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6638981-B2 | Oil-in-water emulsions comprising antidepressant, NMDA receptor antagonist, lipophilic component, water, surfactant; compositions induce local-anesthetic effect when topically administered to intact skin, treating neuropathic pain | EPICEPT CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030082214-A1 | Topical compositions and methods for treating pain | DISCOVER GROWTH FUND, LLC (VI) | 2003-05-01 | — | — | US | disclosed |
| WO-2003034900-A2 | STERILE, BREATHABLE PATCH FOR TREATING WOUND PAIN | EPICEPT CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030082225-A1 | Sterile, breathable patch for treating wound pain | EPICEPT CORPORATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003015699-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EPICEPT CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | DRD3 249/4885CNR2 129/4885CNR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.